Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490698 · ClinicalTrials.gov registry record · Phase 2
Zoledronate With Atorvastatin in Renal Cell Carcinoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00490698: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00490698 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00490698, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Objectives: Primary: Evaluate clinical outcome based on the time to skeletal events after bone-targeted therapy Secondary: 1. Evaluate clinical outcome based on the presence of calcification at the site of osteolytic metastases 2. Measure bone-formation and resorption markers at baseline and during bone-targeted therapy. 3. Assess effect of the bone-targeted regimen on serum cholesterol levels
Interventions
- DRUG Zoledronate
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00490698
The ClinicalTrials.gov registry entry for NCT00490698 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zoledronate is the first listed.
NCT00490698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00490698 about?
NCT00490698 is a clinical study titled "Zoledronate With Atorvastatin in Renal Cell Carcinoma". Objectives: Primary: Evaluate clinical outcome based on the time to skeletal events after bone-targeted therapy Secondary: 1. Evaluate clinical outcome based on the presence of calcification at the site of osteolytic metastases 2. Measure bone-formation and resorption markers at baseline and dur...
What is the current status of trial NCT00490698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2006-10. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00490698?
The interventions under investigation include: Zoledronate (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00490698?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.